Alltracel boosts Japanese firm's woundcare line:
This article was originally published in Clinica
Executive Summary
Alltracel Pharmaceuticals has entered an agreement with Japanese consumer woundcare company Nichiban to develop and market Alltracel's m.doc "stop-bleeding" technology in Japan. The initial focus is to integrate the Dublin, Ireland-based company's SEAL.ON first aid treatment range, which incorporates m.doc's fast coagulating properties, into Nichiban's portfolio of woundcare brands. The Tokyo-based firm, which holds a 23% majority share of the Japanese consumer woundcare market, says it also plans to upgrade its own line-up of existing brands by introducing m.doc technology into the products.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.